source
- Roche’s enicepatide shows dose-dependent blood sugar and weight loss in Phase 2 diabetes trialRoche reported that its injectable GLP-1/GIP dual agonist enicepatide, acquired through the Carmot Therapeutics purchase, achieved reductions in blood glucose and body weight in a Phase 2 study of…
- HHS rolls out new FDA rule to allow non-animal testing methods in drug developmentThe Department of Health and Human Services announced a new set of strategies aimed at shifting drug development away from animal testing toward human-based research methods. The FDA issued a fina…